Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy

Blood

Volumn 98, Issue 12, 2001, Pages 3473-3475

  Corbellino, Mario ^a,b   Bestetti, Giovanna ^a,b   Scalamogna, Chiara ^a,b   Calattini, Sara ^a,b   Galazzi, Morena ^a,b   Meroni, Luca ^a,b   Manganaro, Daniele ^a,b   Fasan, Marco ^a,b   Moroni, Mauro ^a,b   Galli, Massimo ^a,b   Parravicini, Carlo ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; CIDOFOVIR; DOXORUBICIN; INDINAVIR; INTERLEUKIN 6 ANTIBODY; LAMIVUDINE; NEVIRAPINE; RITUXIMAB; STAVUDINE; VINCRISTINE; VIRUS DNA;

ADULT; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CASE REPORT; CLINICAL EXAMINATION; DIAGNOSTIC ACCURACY; DISEASE MARKER; DRUG TOLERABILITY; EPSTEIN BARR VIRUS; FEMALE; GENE SEQUENCE; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REMISSION; SEQUENCE ANALYSIS; SIDE EFFECT; SYMPTOM; TREATMENT INDICATION; VIREMIA;

EID: 0035760321     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.12.3473     Document Type: Article

References (24)

1. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Epstein-Barr virus and Kaposi sarcoma herpesvirus/human herpesvirus 8. Monographs on the evaluation of carcinogenic risks to humans. Lyon, France: International Agency for Research on Cancer; 1997.
2. Parravicini C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV v-IL6, in HIV seronegative Castleman's disease. Am J Pathol. 1998;6:1517-1522.
3. Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol. 1988;5:346-364.
4. Ambroziak JA, Blackbourn DJ, Herndier BG, et al. Herpes-like sequences in HIV-infected and uninfected Kaposi's sarcoma patients. Science. 1995;268:582-583.
5. Parravicini C, Chandran B, Corbellino M, et al. Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. Am J Pathol. 2000;156:743-749.
6. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci U S A. 1999;96:4546-4551.
7. Kuehnle I, Huls MH, Liu Z, et al. CD20 monoclonal antibody (Rituximab) for therapy of EpsteinBarr lymphoma after hematopoietic stem-cell transplantation. Blood. 2000;95:1502-1505.
8. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989:9.14-9.22.
9. Corbellino M, Poirel L, Bestetti G, et al. Restricted tissue distribution of extra-lesional KS-associated herpesvirus-like (KSHV) DNA sequences in AIDS patients with Kaposi's sarcoma. AIDS Res Hum Retrovir. 1996;12:651-657.
10. th General Meeting of the American Society of Microbiology, 1994; Las Vegas, NV. Abstract D256.
11. Parravicini C, Lauri E, Baldini L, et al. Kaposi's sarcoma herpesvirus infection and multiple myeloma. Science. 1997;278:1969-1970.
12. Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602-605.
13. Soulier J, Grollet L, Oksenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86:1276-1280.
14. Corbellino M, Poirel L, Aubin JT, et al. Human herpesvirus-8 DNA sequences and Epstein-Barr virus in giant lymph-node hyperplasia (Castleman's disease). Clin Infect Dis. 1996;22:1120-1121.
15. Grandadam M, Dupin N, Calvez V, et al. Exacerbation of clinical symptoms in human immunodeficiency virus type 1 infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis. 1997;175:1198-1201.
16. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96:2069-2073.
17. Stevens SJC, Verschuuren EAM, Pronk I, et al. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97:1165-1171.
18. Kedes DH, Ganem D. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs: implications for potential therapy. J Clin Invest. 1997;99:2082-2086.
19. Foussat A, Fior R, Girard T, et al. Involvement of human interleukin-6 in systemic manifestations of human herpesvirus type 8-associated multicentric Castleman's disease [letter]. AIDS. 1999;13:150-151.
20. Haddad E, Paczensny S, Leblond V, et al. Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial. Blood. 2001;97:1590-1597.
21. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10:61-67.
22. Dupin N, Diss T, Kellam P, et al. HHV-8 is associated with plasmablastic variant of Castleman's disease that is linked to HHV-8 positive plasmablastic lymphoma. Blood. 2000;95:1406-1412.
23. Cannon JS, Ciufo D, Hawkins AL, et al. A new primary effusion lymphoma-derived cell line that yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant. J Virol. 2000;74:10187-10193.
24. Santambrogio S, Ridolfo AL, Galli M, Corbellino M. Effect of highly active antiretroviral treatment (HAART) in patients with AIDS-associated KS. Proceedings of the 12th World AIDS Conference, June 28-July 3, 1998, Geneva. Abstract 22275.